Stephen Mandel Ascendis Pharma A/S Call Options Transaction History
Lone Pine Capital LLC
- $12.7 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ASND
# of Institutions
211Shares Held
46.5MCall Options Held
310KPut Options Held
306K-
Artisan Partners Limited Partnership Milwaukee, WI5.67MShares$760 Million1.32% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.08MShares$546 Million3.29% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.97MShares$531 Million7.23% of portfolio
-
Janus Henderson Group PLC London, X03.77MShares$505 Million0.32% of portfolio
-
Wellington Management Group LLP Boston, MA2.75MShares$368 Million0.08% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $7.48B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...